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Background: When tests are used in series to determine individual risk factors and infection status in a mass
drug administration (MDA), the diagnostics, test order and subsequent treatment decisions (the testing algo-
rithm) affect population-level treatment coverage and cost, but there is no existing framework for evaluating
which algorithm optimizes any given outcome.
Methods: We present a mathematical tool (with spreadsheet implementation) to analyse the effect of test
ordering, illustrated using treatment for onchocerciasis in an area where high-burden Loa loa co-infections
present a known risk factor.
Results: The prevalence of the infection and risk factor have a non-linear impact on the optimal ordering of
tests. Testing for the MDA infection ﬁrst always leaves more infected people untreated but fewer people with
the risk factor being misclassiﬁed. The cost of the treatment given to infected individuals with the risk factor
does not affect which algorithm is more cost effective.
Conclusions: For a given test and treat algorithm and its costs, the correct strategy depends on the expected
prevalence. In most cases, when the apparent prevalence of the target infection is greater than the apparent
prevalence of the risk factor, it is cheaper to do the risk factor test ﬁrst, and vice versa.
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Introduction
As we approach disease elimination, it becomes increasingly
important to be able to enact interventions everywhere the dis-
ease is endemic. This may require us to revisit communities, or
individuals, in which treatment is complicated by the presence
of risk factors that affect the treatment required, particularly for
mass drug administration (MDA), a mainstay of neglected trop-
ical disease (NTD) control.1 The presence of risk factors can pre-
vent a drug from being safely administered to the whole
population, reducing the coverage of the campaign both
through a reduction in population that can be safely treated
and through reduced local support due to adverse reactions to
the treatment. This undermines the MDA campaign, which
requires high coverage in order to be effective. Although this
problem is particularly relevant for NTDs, it is also seen in other
diseases, and indeed the infrequent use of MDA outside of NTDs
is largely due to the lack of treatments with the right safety
proﬁle.
The combination of risk factors and multiple treatment regi-
mens and diagnostic tests means that the design of the testing
algorithm needs to be carefully considered. For example, there
has recently been renewed interest in the possibility of MDA
campaigns for malaria,2,3 which could be MDA or mass screen
and treat (MSAT).2,4 For an MSAT campaign where pregnancy is
a risk factor,5 there might be a question of whether to offer
women of child-bearing age a pregnancy test or a malaria test
ﬁrst. There are many ethical considerations in this scenario, but
there are also practical, cost and efﬁcacy considerations that
would affect the choice of test and the treatment algorithm.6
Another example of screening forming part of an MDA is for
onchocerciasis in areas that are co-endemic with Loa loa ﬁlaria-
sis. Where these diseases are co-endemic, the usual MDA treat-
ment (ivermectin) has a high risk of severe adverse events
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(SAEs) if the individual has a high Loa loa microﬁlarial (mf)
load.7 Under the current World Health Organization guidelines,
areas with hypo-endemic onchocerciasis prevalence where Loa
loa is known to be present have been left untreated.8,9 The
question of how to eliminate onchocerciasis by delivering safe
treatment in these co-endemic areas has recently been much
debated.10–12 The development of the LoaScope,13 a mobile
telephone–based video microscope, has made testing for Loa
loa in the ﬁeld more practical, leading to the ‘test-and-not-treat
strategy’, where individuals with high Loa loa loads are identiﬁed
through individual-level testing and not treated for onchocercia-
sis. This has recently been shown to be implementable in a
population of more than 20 000 people.8
Prior to this demonstration of ﬁeld implementation, there
were concerns that an approach that required testing the whole
population for Loa loa would be too time consuming for large-
scale screening. In response, there was a proposal to possibly
combine the Loa loa test with an onchocerciasis test and only
use the Loa loa test for a small part of the population. For this
example, the primary aim is to avoid SAEs by constraining the
testing algorithm to ensure that everyone who is given the
standard treatment for onchocerciasis has been tested for Loa
loa. There are two possible testing algorithms (Figure 1):
(1) Screen the population using a risk factor test and then treat
everyone who is negative, increasing MDA treatment cover-
age but, depending on the relative costs of the person-time
running the tests, increasing costs.
(2) Screen with the MDA infection test and only use a risk factor
test on those who are positive for the infection (in our
example, treatment coverage is constrained by the low sen-
sitivity of the onchocerciasis rapid test at low prevalence).
It is not immediately obvious which of these algorithms is
‘best’ in terms of efﬁcacy and cost. This article seeks to address
that question by developing a general framework applying it to
this onchocerciasis/Loa loa example.
It is important to note that since our research was under-
taken a different solution is close to being implemented for
onchocerciasis, in which each implementation unit is mapped to
determine whether both onchocerciasis and Loa loa are present
and, if so, each individual gives a blood sample that is tested for
both diseases before treatment, increasing the sensitivity of the
onchocerciasis test.
However, to our knowledge, the literature still lacks a frame-
work for making a choice between serial testing and treatment
algorithms on the basis of population-level impact. We note that
a related question has been more widely studied in which multiple
tests exist for the same disease, with different costs, speciﬁcities
and sensitivities (e.g., for human immunodeﬁciency virus [HIV]).14
Again, the question of the ordering of these tests, which has been
examined to determine the optimal ordering for diagnosis and
cost, could be addressed using the tool outlined here. Our frame-
work is relevant to any scenario in which a disease is present in a
population that also displays some risk factor that increases the
risk of SAEs when individuals are treated for a disease. It is
important to note that this requires a test for the risk factor for
which the sensitivity and speciﬁcity have been reliably determined
under the circumstances in which the tool will be used.
The three outcomes we wish to balance are the number of
people at risk of SAEs, the number of people infected with the
disease that do not receive treatment and the total cost of the
scheme, including the costs of tests and treatments. Factors that
affect these outcomes include the sensitivities and speciﬁcities of
the tests, the prevalence of the disease and the risk factor and
the costs of the tests and treatments. We describe the method-
ology used in the tool to calculate the outcomes and the general
patterns that emerge. We have produced a spreadsheet tool that
allows the user to specify these different factors and explore their
effects on the described outcomes. We illustrate how the tool
can be used to assess the optimal order of test and treatment
decisions for onchocerciasis scenarios, but the same methods
may be easily applied to compare proposed treatment algo-
rithms for any disease with a co-endemic risk factor.
Methods
We consider a population of individuals, divided into six groups
according to their onchocerciasis infection status (uninfected vs
infected) and three levels of possible Loa loa infection (unin-
fected vs low mf load vs high mf load). How best to specify the
joint distribution of the two diseases (or MDA infection and risk
factor) depends on the set of initial assumptions. If the two dis-
eases are presumed to be independent, then the joint distribu-
tion is just the product of the proportion of individuals with each
disease. In the case of Loa loa, the proportion of the population
that have no, low or high burdens of Loa loa can be speciﬁed by
assuming a negative binomial mf distribution and a threshold
above which the burden is considered to be ‘high’. Alternatively
we can consider that the two infections may be correlated (as
seen by Kelly-Hope et al.15), whereby having one disease may
make infection with the second more likely. While this last speci-
ﬁcation is likely to be the most accurate, it requires additional
data to inform the proportion of the population in each group
and only affects our analysis of how the relative costs of the
two schemes relate to the prevalence of the two diseases.
Note that our analysis of the risk of SAEs and the number of
people with untreated onchocerciasis depends on both the true
infection status of individuals as well as their test results. In
contrast, our analysis of the relative costs of the two schemes
relies only on the outcome of tests and not on the true under-
lying status.
Each of the six groups is then put through the two algorithms:
testing for Loa loa ﬁrst vs testing for onchocerciasis ﬁrst
(Figure 1). At each stage we take into account the speciﬁcity and
sensitivity of that test. For example, if we take a group of size N
that is uninfected with onchocerciasis, then, on average, (1−sp)N
will test positive for onchocerciasis (false positives), where sp is
the speciﬁcity of the test. Conversely, in a group of size N that is
infected with onchocerciasis (1−sens)N will test negative (false
negatives), where sens is the sensitivity. This procedure gives, for
each of the six groups, the proportion that receives each of the
different treatments, and thus the number at risk of SAEs and
the number that are infected with onchocerciasis but are not
treated. In addition, we calculate the total cost of the algorithm
using the apparent prevalences of the various subgroups.
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Spreadsheets implementing this analysis assuming either inde-
pendence of the two diseases (TestnTreat_prevalences_independent.
xlsx) or requiring co-infection information (TestnTreat_prevalences_
independent.xlsx) are provided as supplementary ﬁles.
Assumptions
Since the difference between negative and low burdens of Loa
loa has little impact on treatment decision in our analysis, we
will simplify the analysis by assuming that the Loa loa test
always correctly identiﬁes the presence or absence of Loa loa.
Therefore in this article, the speciﬁcity and sensitivity of the Loa
loa test refer only to whether the individual has a high or low
mf burden. It would be straightforward to compute a similar
analysis including uncertainty between negative and low Loa
loa tests, and our results would still hold.
Results
We now present an analysis of the two algorithms in Figure 1
using the groups found in Table 1.
Testing for MDA infection ﬁrst always results in more
untreated infected people
In general, using the MDA infection or, in the example, oncho-
cerciasis test ﬁrst results in a larger proportion of people who
are infected with onchocerciasis and are not given a treatment.
This can be seen by calculating the number of infected people
that are untreated under each scheme. If +NO is the number of
people who have onchocerciasis and we test for onchocerciasis
ﬁrst, then the number of untreated infected people is simply
those who incorrectly tested negative for onchocerciasis, that is,
( − ) ( )+N1 O , 1sens O
where Osens is the sensitivity of the onchocerciasis test.
Conversely, if we test for Loa loa ﬁrst, then some people who
would incorrectly test negative for onchocerciasis instead ﬁrst
test negative or low for Loa loa and thus receive treatment any-
way. More speciﬁcally,
( − )(( − ) + ) ( )+ +N L N1 O 1 L 2O Osens sp L , sens L ,L H
is the number of people infected with onchocerciasis who are
untreated, where Lsp and Lsens are the speciﬁcity and sensitivity
of the Loa loa test, respectively, and +NL ,OL and +NL ,OH are the
number of onchocerciasis-positive people who have low and
high Loa loa burdens, respectively. Since + ≤+ + +N N NL ,O L ,O OL H and
(1−Lsp),Lsens≤1, then
( − )(( − ) + )≤( − ) ( )+ + +N L N N1 O 1 L 1 O 3O Osens sp L , sens L , sens OL H
and so testing for onchocerciasis ﬁrst results in more untreated
infected people than testing for Loa loa ﬁrst. More generally, if
one test can lead directly to individuals not being considered for
treatment (and the other does not), then doing that test ﬁrst
will lead to more untreated individuals.
Testing for MDA infection ﬁrst always results in fewer
people at risk of SAEs
For similar reasons, testing for onchocerciasis ﬁrst also results in
fewer people at risk of SAEs. In this case, people who have high
Loa loa burdens and receive an MDA treatment are considered
to be at risk of SAEs. Similar to the above section, there will be
fewer people in this category when testing for onchocerciasis
ﬁrst, since some people who have high Loa loa burdens will
(rightly or wrongly) test negative for onchocerciasis and thus
receive no treatment. We may again calculate the number of
people at risk of SAEs under each scheme. When the Loa loa
test is given ﬁrst, the number of people with a high Loa loa bur-
den that (incorrectly) test low for Loa loa (and thus are at risk of
SAEs) is given by
( − )( + ) ( )+ −N N1 L , 4O Osens L , L ,H H
(a)
(b)
Figure 1. Example algorithms for test and treat for onchocerciasis and
Loa loa. (a) Loa loa ﬁrst. (b) Onchocerciasis ﬁrst. The proportion of the
population going down each part of the test-and-treat pathway
depends on which test is administered ﬁrst and the apparent prevalence
of the MDA infection and the risk factor. Total costs depend on the pro-
portion of the population that are given each test and the proportions
taking each treatment.
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where −NL ,OH is the number of people with a high Loa loa burden
without onchocerciasis. Conversely, if the onchocerciasis test is
given ﬁrst, then only those testing positive for onchocerciasis
will be considered for treatment and of these, some will incor-
rectly test low for Loa loa. The following population,
( − )( +( − ) ) ( )+ −N N1 L O 1 O , 5O Osens sens L , spec L ,H H
will therefore be at risk of SAEs. Since Osens≤1 and (1−Osp)≤1,
then
( − )( + )( − )( +( − ) )
( )
+ − + −N N N N1 L 1 L O 1 O ,
6
O O O Osens L , L , sens sens L , spec L ,H H H H
and so testing for onchocerciasis ﬁrst always results in fewer
people at risk of SAEs than testing for Loa loa ﬁrst. In general, if
one test leads directly to people not being treated, and there is
a risk of SAEs, then doing that test ﬁrst will result in fewer peo-
ple at risk of SAEs.
Costs of the two schemes
The tests and treatments that would be given under the two
schemes are summarised in Table 1. The population is divided
into six subpopulations based on their test results for the two
diseases, then for each subpopulation we give the tests and
treatments given for that subpopulation under the scheme. So,
for example, if an individual tests positive for onchocerciasis
(either because they have onchocerciasis or because they
receive a false positive on the test) and demonstrates a low Loa
loa burden on their test, then on the Loa loa–ﬁrst scheme (algo-
rithm A) they will receive the Loa loa test and, on the basis of
that, will be given the MDA treatment and will then be moni-
tored for side effects. On the onchocerciasis-ﬁrst scheme (algo-
rithm B) they will be given the onchocerciasis test and, on the
basis of that, will be given the Loa loa test and, on the basis of
those two results, will receive MDA treatment plus monitoring
for side effects.
The cost of the alternative treatment does not affect
which scheme is more cost effective
To determine which scheme is more efﬁcient we only need to con-
sider the differences between the two schemes. In particular, the
alternative treatment is only given to people who test positive for
onchocerciasis and test high for Loa loa. Since this is the subgroup
that we are required to identify, this group always receives both
tests and the alternative treatment. Therefore the cost of the alter-
native treatment does not affect which scheme is less expensive.
Which is cheaper?
The price of tests and treatment depends only on the outcomes
of those tests and not the true disease status of the individuals
tested. We will therefore deﬁne NXT to be the number of people
that test as X. For example, −NTL Oh is the number of people that, if
they were tested, would present with a high Loa loa burden and
would be negative for onchocerciasis, regardless of their actual
disease status. The difference in cost between the two schemes
can be seen by using the information in bold in Table 1. This is
given by (Loa loa ﬁrst—onchocerciasis ﬁrst):




− − + +
N O N L
N N N
MDA L MDA O




L O test test L O test test
L O test L O test L O test
L
H L
where Ltest, Otest, [MDA] and [MDA]
+ are the costs of the Loa loa test,
onchocerciasis test, MDA treatment and MDA treatment plus obser-
vation, respectively. Rearranging and using + =− − − + −N N NT T TL O L O L ,
+ =− +N N NT T TL O L O LL L L and + + =− − − − −N N N N
T T T T
L O L O L O OL H , we obtain
Table 1. Tests and treatments employed for each algorithm (see Figure 1) stratiﬁed by how individuals test for the two diseases. Differences
between the two schemes are highlighted in bold
(a) Loa loa test ﬁrst (algorithm A)
Loa loa test result
− Low High













(b) Onchocerciasis test ﬁrst (algorithm B)
Loa loa test result
− Low High
Onchocerciasis test result − Onchocerciasis test Onchocerciasis test Onchocerciasis test
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− ( + )+[ ] +[ ] ( )+− − − − −N O N N N NL MDA MDA . 8T T T T Ttest O test L L L O L OL L
We may see from this that the Loa loa–ﬁrst scheme (algo-
rithm A) is more likely to be cheaper at lower onchocerciasis
prevalences and/or when the Loa loa test, the MDA treatment or
the MDA treatment with observation are more expensive.
Up to this point we have made no assumptions about how
the prevalence of the two infections affect each other. For
example, it may be the case that individuals with onchocerciasis
are also more likely to have high loads of Loa loa. To progress
with the analysis from here, however, we will assume that the
two infections (and testing positive for the infections) are inde-
pendent of each other. That is, individuals infected with oncho-
cerciasis are no more or less likely to have Loa loa infections. It
is convenient at this point to use apparent prevalences
( =n N N/XT XT ) rather than populations (NXT ), so that combinations
of populations are easily calculated. For example, the fraction of
the population that tests negative for Loa loa and positive for
onchocerciasis is given by =− + − +n n nT T TL O L O , and equation (8)
becomes
− ( − )+[ ] ( − )+[ ] ( − )
( )
+− − + +n O n n n n nL 1 MDA 1 MDA 1 ,
9
T T T T T Ttest O test L L O L Oh L
using = −− +n n1T TO O and + + −−n n n1
T T T
L L LL h
. Solving equation (9) to ﬁnd
when the two schemes are equal gives
= –
( − )














For +nTO greater than in equation (10), it is cheaper to do the
Loa loa test ﬁrst, whereas for lower onchocerciasis prevalences
it is cheaper to do the onchocerciasis test ﬁrst (algorithm B). It
is intuitive that low onchocerciasis prevalences result in the
onchocerciasis-ﬁrst algorithm being cheaper, since people who
test negative for onchocerciasis receive no further tests or treat-
ment. Figure 2a gives an indication of the shape of these differ-
ent regions. We note that nT
LH
is at most −n1 T
LL
, since we keep nT
LL
as a parameter and require that + + =−n n n 1T T T
L L LH L
.
Since the costs of the various tests and treatments may be
variable depending on the situation, we explore the effect of
changing these parameters on this plot. It is clear from equa-
tion (10) that the price of the onchocerciasis test merely scales
with changes in the other parameters. In addition, increasing
the apparent prevalence of low Loa loa burdens (nT
LL
; Figure 2b),
increasing the price of the Loa loa test (Ltest; Figure 2c) or
decreasing the price of MDA treatment with observation
([MDA]+; Figure 2e) will have a similar effect. All of these
changes will increase the number of positive onchocerciasis test
results required before the Loa loa–ﬁrst scheme (algorithm A)
becomes cheaper. Increasing the price of MDA treatment, how-
ever, will lead to a more curved dividing line, so that the region
in which the onchocerciasis-ﬁrst scheme is cheaper becomes
much larger (Figure 2d). This is due to the subpopulation with
negative onchocerciasis and Loa loa results being untreated in
the onchocerciasis-ﬁrst scheme (algorithm B), while receiving
MDA treatment under the Loa loa–ﬁrst scheme. Since more peo-
ple receive MDA treatments under the Loa loa–ﬁrst scheme, this
becomes more expensive as the cost of the MDA treatments
increases.
Conclusions
We have presented an analysis of two test-and-treat schemes:
testing for the disease ﬁrst or for the risk factor ﬁrst. In our
example scenario, the disease is onchocerciasis and the risk factor
is co-infection with Loa loa. This illustrates that testing for the dis-
ease ﬁrst (algorithm B) will always result in more untreated
infected people, but it will also result in fewer people at risk of
SAEs. We note that if the sensitivity of the risk factor test is 100%
(as is given for Loa loa by D’Ambrosio et al.13), then there are no
people at risk of SAEs from either scheme. In this case the
scheme used will depend on the relative costs of the two possibil-
ities. At low MDA infection prevalences the risk factor–ﬁrst scheme
is likely to be cheaper and, since it will result in fewer untreated
infected people, would be the better choice (assuming 100% risk
factor test sensitivity). At higher MDA infection prevalences, how-
ever, the MDA disease test–ﬁrst scheme (algorithm B) may be
cheaper and so the decision may rest on how much each add-
itional treated person costs. For any particular circumstance this
may be calculated as ( − )( −( − ) − )+ + +N N N1 O 1 L Lsens O sp L ,O sens L ,OL H
divided by equation (8). Note that to determine this it may be
necessary to use the speciﬁcities and sensitivities of the diagnos-
tics to convert between true underlying prevalences and the pro-
portion of positive test results. We have provided a spreadsheet
tool to assist with determining the relative costs and beneﬁts of
the schemes with given test and treatment costs and prevalences
of the two diseases (see supplementary ﬁle).
It should be noted that we only consider here the risk of SAEs,
the cost of the schemes and the proportion of infected people
receiving treatment. The tool does not consider practicalities such
as the need to take blood samples at a particular time of the day
due to the diurnal periodicity of the Loa loa microﬁlaria. Nor does
the tool consider speciﬁc diagnostic tools. To test for Loa loa, one
could use the CellScope Loa test, which has been shown to have
94% speciﬁcity and 100% sensitivity13 and requires blood samples
in the middle of the day.16 For onchocerciasis one could use the
rapid format OV-16 antibody test,17 which has demonstrated sensi-
tivities between 76.5% and 81.1% with 100% speciﬁcity. We note
that the OV-16 test was developed as a tool for mapping the preva-
lence of onchocerciasis, not as a diagnostic test to determine when
individuals receive treatment, as antibody tests cannot distinguish
between past and current infections. Nonetheless, the tool pre-
sented here is not test dependent and can be used in any situation
in which the accuracy and cost of the different tests, the disease
and risk factor prevalences and the cost of treatments are known.
The situation considered here shares some similarities with the
question of parallel vs serial tests that has been analysed for dis-
eases such as HIV14,18 or canine Leishmaniasis.19 However, when
considering parallel vs serial tests, we are usually looking at using
multiple tests to improve the sensitivity and speciﬁcity of diagnos-
ing a single disease. For example, one might consider using a test
with a high sensitivity but low speciﬁcity ﬁrst, then using a high spe-
ciﬁcity test on those that tested positive to reduce the number of
false positives. Alternatively, one could use both tests in parallel
and consider the individual to be positive if he/she test positive on
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either test, thus increasing the sensitivity at the expense of a lower
speciﬁcity. Instead, we consider a case in which we are testing for
two different diseases or risk factors in order to determine the cor-
rect treatment strategy.
The following results are generically true in the context of
MDA with a risk factor. If one test can lead to untreated indivi-
duals (and the other does not), then doing that test ﬁrst will lead




Figure 2. Investigating the effect of changing test and treatment prices on which scheme is cheaper. (a) The top dividing line shows where the two
schemes cost an equal amount taking the parameter values: [ ]= [ ] = = = =+ nMDA 0.5, MDA 1, O 2, L 1, 0.2Ttest test LL . (b)–(e) We change different values in
the way indicated by the arrow to go from the bottom dividing line to the top dividing line. Note that the prevalence of high Loa loa test results (nT
Lh
)
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to people not being treated, and there is a risk of SAEs, then
doing that test ﬁrst will result in fewer (or equal) people at risk of
SAEs. In addition, if the aim of both schemes is to identify a spe-
ciﬁc subpopulation in order to administer a given treatment (the
‘alternative treatment’ in our scenario), then the cost of that
treatment does not affect which scheme is more expensive.
Supplementary data
Supplementary data are available at Transactions online (http://
trstmh.oxfordjournals.org/).
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